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Abstract: 
 Mutations in the BReast CAancer suspectibility genes BRCA 1 and 2 account for 
approximately 10% of breast cancers and 15% of ovarian cancers. Individuals with a 
mutation in these genes (and a resulting impairment in the function of these genes in e.g. 
DNA repair and estrogen signaling) have a much higher risk for getting these cancers 
than the population at large. This review aims to provide comprehensive information for 
BRCA mutation carriers on currently available options to lower the risk of getting cancer. 
The review summarizes interaction of lifestyle/environmental factors, such as diet, 
alcohol consumption, and hormonal supplements, in key pathways and mechanisms 
involved in cancer onset via a role in estrogen metabolism and DNA repair. This review 
furthermore evaluates promising future research directions and concludes that (i) more 
BRCA testing needs to be conducted on broader populations, (ii) BRCA1 and BRCA2 
need to be analyzed separately as they exhibit distinct characteristics, and (iii) studies on 
lifestyle factors need to include multiple, synergistically acting factors and lifestyle 
history from many years prior to diagnosis. Additionally, (iv) molecular diagnostics and 
gene therapy provide promising results for hereditary cancers and need to be moved 
forward as quickly as possible. Furthermore, (v) research seems to be hindered by a lack 
of interdisciplinary collaboration, and should greatly benefit from a more synergistic 
effort. Finally (vi) lifestyle and diet changes can be made immediately to lower cancer 
risk for BRCA mutation carriers.  
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1. Introduction 
 Breast cancer is one of the most common cancers and affects millions of people 
worldwide (Siegel et al., 2012). Breast cancer awareness in general, as well as funding 
for research and life-saving early detection, has been on the rise (Siegel et al., 2012). 
However, little is known about hereditary breast cancer associated with BRCA (BReast 
CAncer susceptibility genes). BRCA1 and 2 are “tumor suppressor genes” that, when 
rendered nonfunctional by mutations, cause high penetrance (percent of people with the 
gene who actually get cancer) of breast and ovarian cancer (Christopoulou and Spiliotis, 
2006). For my thesis, I conducted a comprehensive literature review of BRCA to identify 
what is known today and on what areas future research should focus. I reviewed and 
summarized current knowledge of the roles of (1) genetics (population and molecular 
genetics) and (2) environment (diet and hormonal supplements), as well as where efforts 
to utilize (3) molecular diagnostics and gene therapy stand at this time. I concluded that 
there is evidence for roles of multiple different genetic and environmental factors in 
BRCA-associated cancer (and breast cancer overall), but that research has been focused 
on each factor in isolation and now urgently needs to be conducted in a comprehensive, 
integrative way to assess synergistic effects among different factors. Furthermore, many 
current studies treat BRCA1 and BRCA2 as equivalent, despite the fact that these two 
genes generate tumors with different characteristics (Foulkes et al., 2004) and should 
therefore be analyzed individually. I furthermore identify promising targets of future 
research on molecular diagnostics and gene therapy. Finally, I identify lifestyle changes 
that BRCA mutation carriers can make immediately to lower risk for cancer. 
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2. Defining BRCA 
 As stated above, BRCA1 and 2 stand for BReast CAncer susceptibility genes 1 
and 2, and are tumor suppressor genes everyone possesses in his/her own genome 
(Christopoulou and Spiliotis, 2006). Tumor suppressor genes are genes that, in their 
normal, un-mutated form, help to suppress tumor formation and prevent cancer via key 
pathways. Hundreds of mutations in these two genes have been identified (Borg et al., 
2010). Such mutations in these two genes are significantly correlated with a high risk for 
breast and ovarian cancer, and also exhibit apparent correlations with increased risks for 
cervical, uterine, pancreatic, stomach, peritoneal, and prostate and testicular cancer in 
men (Brose et al., 2002). 
 While DNA naturally accumulates mutations over time (Hanahan and Weinberg, 
2000), mutations are normally either removed via repair of mutated DNA, or mutated 
cells are not allowed to divide (through cell cycle checkpoints controlling cell division 
rate) and/or are committed to programmed cell death (apoptosis) (Hanahan and 
Weinberg, 2000). It is when cells sustain mutations specifically inhibiting the latter key 
protective pathways (e.g. DNA repair or control of cell proliferation and cell death) that 
cells with mutated DNA are able to divide uncontrollably and produce cancer (Hanahan 
and Weinberg, 2000). Functional copies of BRCA1 and BRCA2 apparently prevent 
cancer via e.g. DNA repair (Boulton, 2006) and control of estrogen signaling (Li, 2007). 
Specifically, DNA repair proceeds via DNA double strand break repair by homologous 
recombination and by locating double strand breaks, nucleotide excision repair, cell cycle 
checkpoint control, ubiquitylation of proteins, chromatin remodeling, and more, with all 
of the latter processes being involved in tumor suppression (Boulton, 2006). Control of 
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estrogen signaling by functional BRCA genes involves e.g. an inhibitory effect on 
estrogen signaling via estrogen receptor-alpha (Li, 2007; for more detail, see below). A 
faulty, mutated copy of one of the BRCA genes means that the body has fewer tools to 
prevent cancer formation, and the risk of breast and ovarian cancer thus increases, 
presumably especially if BRCA mutations are combined with other factors (or mutations) 
that increase cell division rate, prevent programmed cell death, and/or prevent DNA 
repair.  
 The two BRCA genes are inherited in an autosomal dominant manner, meaning 
that they are located on chromosomes (two different autosomal chromosomes) other than 
sex chromosomes, and that just one faulty copy (as opposed to two copies in a recessive 
disorder) of the dominant gene is enough to increase cancer risk (Christopoulou and 
Spiliotis, 2006). Thus, only one mutated copy of the gene needs to be inherited (from one 
parent) to result in increased susceptibility for breast and ovarian cancer. 
 The BRCA genes exhibit a high, but not complete, level of penetrance 
(Christopoulou and Spiliotis, 2006), as the percentage of individuals with a faulty copy of 
the gene that get cancer. In the normal population, breast cancer risk is around 12% and 
ovarian cancer risk is around 1.4% (Siegel et al., 2012). For individuals with a BRCA 
mutation, around 60% will develop breast cancer and around 15-40% will develop 
ovarian cancer before age 75 (Christopoulou and Spiliotis, 2006).   
 Although the BRCA genes have similar names and related function, they do 
exhibit distinct characteristics in the majority of the tumors they produce (Folks et al., 
2004). One such difference is that around 80% of BRCA 2 tumors contain estrogen 
receptors (are estrogen receptor positive, ER+), while only 20% of BRCA1 tumors are 
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ER+ (and 80% are ER-, and contain little to no estrogen receptors) (Folks et al., 2004). 
The presence of estrogen receptors is important for impacts on tumor survival since 
estrogen stimulates breast tumor growth (Anderson, 2002). Estrogen-receptor-positive 
(ER+) tumors respond to the presence of estrogen with cell division and increased growth 
(Anderson, 2002). Estrogen-receptor-negative (ER-) tumor cells exhibit few or no 
estrogen receptors, and estrogen is thus unable to stimulate cell division and tumor 
growth (Anderson, 2002). This distinction between BRCA1 and 2 is important for the 
following discussion of the influence of lifestyle on a BRCA mutation carrier’s risk. 
Furthermore, normal BRCA1 suppresses estrogen signaling, and thereby inhibits the 
effect of estrogen in stimulating DNA synthesis and cell proliferation (Li, 2007; Santen, 
2003, 2009; Welboren, 2009). Therefore, individuals with a faulty BRCA are highly 
sensitive to estrogen.  
 
3. Geographic Distribution of BRCA Genes in Human Populations 
 Inherited copies of mutated BRCA genes have been found in human populations 
worldwide and are not confined to a single population, race or ethnicity, as established by 
BRCA studies conducted in e.g. Vietnam (Ginsburg, 2011), Russia (Suspitsin et al., 
2009), the Philippines, Southern China, Japan, Eastern India (Liede and Narod, 2002), 
Brazil (Machado and Almeida, 2011), Morocco (Laraqui et al., 2013), Costa Rica 
(Gutierrez Espeleta et al., 2012), Canada (Dennis, 2011), the United States (Gallion and 
Smith, 1994), France (Caputo et al., 2012), Mexico (Calderon-Garciduenas et al., 2005), 
Puerto Rico (Dutil et al., 2012), Czech Republic (Zikan, 2005), Venezuela (Lara et al., 
2012), Greece (Koumpis et al., 2011) and more. However, certain populations were 
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reported to have a higher prevalence of BRCA mutations, with the best known example 
being the Ashkenazi Jewish population, in which 1 in 40 individuals tests positive for a 
BRCA mutation (Struewing et al., 1997; Warner et al., 1999). However, the Netherlands, 
Sweden, Iceland and a population of French Canadians all exhibit high prevalence levels 
as well (Tonin, 2006; Ferla, 2007; Tryggvadottir, 2006). 
 The “founder effect”, loss of genetic variation upon establishment of a new 
population by a few founding individuals, may be responsible for these high prevalence 
levels (Ferla et al., 2007). The founder effect not only creates an initial loss of genetic 
diversity from the original population, but also continues to create inbreeding and 
accumulation of deleterious mutations. The founder effect has been implicated in high 
BRCA prevalence of certain populations since many individuals share only a few 
common BRCA mutations in these populations (Ferla et al., 2007; Gutierrez Espeleta et 
al., 2012; Laraqui et al., 2013). 
 Although it is known that some populations have higher prevalence levels for 
BRCA than others, the exact BRCA prevalence level is unknown for many countries and 
ethnicities (although, see population references above). Furthermore, little is known 
about causes for differences in prevalence level other than the founder effect. External 
factors related to the physical environmental, such as diet, hormone supplement use, and 
pollutants, are likely to contribute to such differences via their effect on components of 
key pathways controlling cell division, programmed cell death, DNA repair, DNA 
methylation (involved in epigenetic effects that can modify the genome for a few 
generations), and estrogen metabolism and signaling (Hanahan and Weinberg, 2000; 
Surh, 2003; Gullett et al., 2010; for more detail, see section 4 below). In addition, unique 
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genetic interactions may also contribute to this difference in populations. Genes other 
than BRCA, such as those encoding growth factors and receptors, have been shown to 
have a multiplicative effect on breast cancer risk (Henderson and Feigelson, 2000; 
Henningson, 2011). I speculate that certain human populations may have higher or lower 
rates of these additional genes contributing to different risk levels for this polygenic 
disease. Few studies exist on this subject to date, and the few that do typically involve 
testing families of related individuals, and thus do not have a large enough sample size 
and statistical power to allow generalizations (Liede and Narod, 2002; Gutierrez Espeleta 
et al., 2012; Laraqui et al., 2013). The solution to this problem/limitation is testing of a 
large numbers of individuals, including random testing of the population at large rather 
than testing of only high-risk BRCA carriers with either a family history of the disease, or 
a diagnosis with breast or ovarian cancer at a young age. I conclude that such broad-scale 
studies of prevalence rates combined with penetrance and survival rates are urgently 
needed. 
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Figure 1: Schematic depiction of key pathways involved in breast cancer formation, their 
relationship to BCRA mutations, and their modulation by environmental factors.  The 
two boxes shown focus on estrogen signaling leading to cell division (left box 1) and the 
involvement of estrogen metabolites in causing DNA damage (right box 2). Black arrows 
indicate the steps of the mechanistic pathways; green arrows indicate stimulation; red 
arrows and red T indicate inhibition.  The BRCA on this scheme refer to normal un-
mutated BRCA genes. ER-aplha= estrogen receptor alpha, HRT= Hormone replacement 
therapy: used to reduce menopausal symptoms, SP1: “specificity protein 1”, AP1: 
“activating protein 1” AP1, NF-kB: “nuclear factor” all supporting cell proliferation, 
angiogenesis (development of new blood vessels supporting tumor growth), and survival 
and differentiation of cells. c-myc and Cyclin D= both known as cancer-promoting genes 
when mutated, promote cell division. The FA-BRCA pathway is a DNA damage-
activated signaling pathway that controls DNA repair and cell cycle checkpoints. 
(Anderson, 2002; Killinger, 2005; Li, 2007; Gorski, 2009;Welboren, 2009; Santen, 2009; 
Dennis, 2011; Cibula, 2011; Brooks and Zakhari, 2013) 
 	  
4. Comprehensive overview of lifestyle differences and their implications for BRCA 
mutation carriers 
Figure 1 shows estrogen as a key component in cancer formation acting via 
stimulation of either cell proliferation or DNA damage (Santen, 2009). Estrogen can bind 
to estrogen receptors (e.g. ER-alpha) and promote DNA synthesis, cell proliferation, and 
cell division (Box 1); estrogen metabolites can promote DNA damage that, in the absence 
of sufficient DNA repair, can lead to the onset of cancer as a result of mutations in key 
tumor suppressor genes (Box 2) (Anderson, 2002; Santen, 2009).  
 Figure 1 also depicts functions of BRCA genes; normal BRCA1 inhibits ER-alpha 
signaling (Li, 2007; Gorski et al., 2009). The relationship between BRCA1 and estrogen 
signaling is complex; estrogen increases the expression of normal BRCA1 and normal 
BRCA1 simultaneously induces ER-alpha synthesis and inhibits subsequent ER-alpha 
signaling (Gorski et al., 2009). 
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 Figure 1 also shows how various lifestyle factors addressed in this review affect 
key pathways leading to breast cancer. Alcohol consumption, certain dietary fats such as 
omega-6 polyunsaturated fats (which promote cell division), and saturated fats (which 
promote obesity and production of estrogen in these fat cells), and hormonal supplements 
all increase the levels of estrogen and/or cell division (Killinger, 2005; Dennis, 2011; 
Cibula, 2011). Alcohol is thought to increase circulating estrogen levels and may also 
stimulate signaling pathways leading to cell division (Brooks and Zakhari, 2013). 
Furthermore, the endogenous hormone melatonin inhibits estrogen production, and lack 
of sleep is known to cause disruption in melatonin production (Mihu, 2009; Merklinger-
Gruchala, 2008). In addition, a multitude of dietary compounds (“phyto”-chemicals for 
“plant”-chemicals found in fruits, vegetables, herbs, and spices) inhibit multiple 
components of (i) signaling pathways controlling cell division as well as (ii) estrogen 
biosynthesis/signaling, (iii) angiogenesis (formation of cancer cell-supporting blood 
vessels), and (iv) stimulate programmed cell death and DNA repair (Surh, 2003; 
Kotsopoulos and Narod, 2005; Gullett et al., 2010; Vera-Ramirez et al., 2013)  
 In addition, multiple genetic interactions can affect estrogen levels and production 
or suppression of estrogen receptors (Fig. 1). A review by Welboren (2009) summarizes 
interactions between estrogen and estrogen-receptor-alpha (ER-alpha) and activation of 
transcription factors (e.g. “specificity protein 1”, “activating protein 1” AP1, and “nuclear 
factor” NF-kB) supporting cell proliferation, angiogenesis (development of new blood 
vessels supporting tumor growth), and survival and differentiation of cells. Additional 
ER-alpha-regulated genes promoting cell division include c-myc and Cyclin D (both 
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known as cancer-promoting genes when mutated; Dubik et al., 1987; Altucci et al., 
1996).  
 
 4. 1. Dietary Factors Associated with Overall and BRCA-related Cancer Risk 
 Many studies have been conducted on the effects of diet on overall breast cancer 
risk in the normal population. A diet low in fat and alcohol and high in fiber, vegetables 
and soy is thought to lower overall breast cancer risk (Morch, 2007; Ellison, 2001; Linos 
et al., 2010; Patterson et al., 2010; Ferrari et al., 2013). These latter findings are 
consistent with the multiple roles of phytochemicals and other dietary factors in 
modulating cancer-related key pathways (Fig. 1). 
 The present study focused on the effect of diet on BRCA mutation carriers, to 
evaluate whether similar or different conclusions may apply to the latter population 
compared to the normal population. A study done in Canada addressed whether diet 
quality affected breast cancer risk for BRCA mutation carriers (Ghadirian, 2009). Many 
French-Canadians, including 738 with diagnosed breast cancer and involving 38 BRCA 
carriers, were included in the latter study. Assessment of diet through a food 
questionnaire revealed that a diet rich in vegetable and fruit diversity was correlated with 
a reduced risk for breast cancer for BRCA mutation carriers (Ghadirian, 2009). Earlier 
studies by the same author showed that “healthy eating” in general, as described by the 
Canadian Healthy Eating Index and the Diet Quality Index-Revised, is also correlated 
with a reduced breast cancer risk for BRCA mutation carriers (Nkondjock and Ghadirian, 
2007). These “healthy” diets involve consumption of diverse fruits, vegetables, grains as 
well as dairy, poultry and fish. An even earlier study had reported that a lower Body 
Mass Index (ratio of weight to height) and/or the loss of weight between the ages of 18 
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and 30, was correlated with a reduced breast cancer risk in BRCA mutation carriers 
(Kotsopoulos, 2005). This observation is consistent with findings by Lagiou (2009) in 
Greece that women who ate more mono- and polyunsaturated fats (as opposed to 
saturated fats) in the year prior to their diagnosis had tumors that expressed higher levels 
of estrogen-receptor-alpha. This latter study, along with another study on polyunsaturated 
fats in 2005 (Hilakivi-Clarke, 2005) suggests that high levels of specifically omega-6 
fatty acids increase cell proliferation and therefore risk for breast cancer.  
Furthermore, an inverse relationship between consumption of high levels of fruits 
and vegetables with a lower risk for cancer is supported by hundreds of studies (Surh, 
2003). Recent research is focused on phytochemicals found in vegetables and their 
regulation of the pathways in Boxes 1 and 2 of Figure 1 (Anderson, 2002; Surh, 2003; 
Gullett et al., 2010). Such dietary phytochemicals can help prevent cancer by promoting 
numerous tumor suppressor genes and repressing oncogenes, inhibition of angiogenesis 
(the production of new blood vessels by cancerous tumors which promotes rapid growth), 
promotion of DNA repair, up regulation of immune responses and more (Gullett et al., 
2010). 
 The effect of alcohol consumption on BRCA mutation carriers is another lifestyle 
factor that has been implicated (see Fig. 1; Dennis, 2011). Only a few studies have 
addressed how alcohol affects BRCA mutation carriers. A study by Dennis (2011) in 
Canada addressed the effects of alcohol on BRCA mutation carriers separately for the 
two genes involved, i.e. BRCA1 and BRCA2, and reported no significant relationship 
between alcohol consumption and breast cancer in carriers of BRCA1 mutations (Dennis, 
2011). On the other hand, drinking red wine was suggested to be beneficial for these 
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latter individuals, perhaps due to a beneficial effect of the phytochemical resveratrol 
found in red wine (Fustier et al., 2004; Delmas et al., 2006).  
 Dennis (2011) found that overall increased alcohol consumption, specifically 
excluding red wine (with its high resveratrol content), was correlated with a higher 
breast cancer risk for carriers of BRCA2 mutations. The latter study suggests that the 
effects of alcohol on breast cancer risk are greater specifically for carriers of BRCA 2 
mutations than for BRCA1 mutation carriers or the general population without BRCA 
mutations. Furthermore, this increased risk for BRCA2 mutation carriers was greater in 
women with a Body Mass Index over 25 and in women who’ve had a child (Dennis, 
2011). A relationship between obesity and breast cancer may involve fat cells that can 
contribute to estrogen levels by converting androstenedione to estrone in adipose tissue 
(Killinger, 2005). 
 The conclusion that alcohol differentially affects certain BRCA mutation carriers 
is further supported by a study showing that alcohol damages DNA and specifically 
activates the FA-BRCA pathway for DNA repair (Abraham, 2011; see Fig. 1). The FA-
BRCA pathway is a DNA damage-activated signaling pathway that controls DNA repair 
and cell cycle checkpoints. Furthermore, alcohol down-regulates mRNA and protein 
levels of BRCA1 (Fan, 2000). Additionally, alcohol increases (i) circulating estrogen 
levels in the body (Reichman et al., 1993; Dorgan et al., 2001; Fan, 2000) and (ii) the 
sensitivity of estrogen receptors to estrogen levels (Fan, 2000). BRCA1 normally 
suppresses estrogen-receptor-alpha signaling, and alcohol partially reverses the 
repression.  
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 As stated above, BRCA 1 and BRCA 2 differ in their estrogen-receptor status, 
with around 80% of BRCA 2 tumors being ER+ (showing a high presence of estrogen 
receptors) while 80% of BRCA1 tumors are ER-. In comparison, around 60% of tumors 
found in individuals not carrying a mutated BRCA gene are ER+ (Singletary, 2001).  
These features offer an explanation of the results of Dennis (2011), where (the ER-
positive) BRCA2 mutation carriers, but not (the ER-negative) BRCA1 mutation carriers, 
were found to have an increased risk for cancer from alcohol consumption. Li (2009) 
further confirms the correlation between a higher risk of ER+ breast cancer and alcohol 
consumption. However, the alcohol history of patients recorded by Dennis (2011) was 
only taken during the year prior to breast cancer diagnosis and it is known that cancer 
grows in the body for long periods of time before diagnosis (Patrone, 2011). This is a 
major design limitation in the study by Dennis (2011) and other lifestyle questionnaire 
studies that only obtain recent history. I conclude that future studies are needed that 
compare life-long alcohol consumption to the risk for breast cancer. 
 
 4. 2. Hormonal Supplements and BRCA 
 Although it seems intuitive that hormone supplements would affect the 
occurrence of breast and ovarian cancer, as cancers of the reproductive organs, limited 
research is available on the specific effects of hormones on BRCA mutation carriers. 
Nevertheless, this limited research proves insightful for ovarian cancer risk. 
 There is evidence that estrogen-based contraception can protect against ovarian 
cancer, while possibly stimulating the risk for breast cancer (see below). Many studies 
have suggested a protective effect of oral contraceptives for ovarian cancer risk in the 
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normal population, and six studies specifically addressed the effect of oral contraceptives 
on BRCA mutation carriers. Five out of these six studies concluded that ovarian cancer 
risk is reduced as a result of oral contraceptive use for both BRCA 1 and BRCA 2 
mutation carriers (Narod et al., 2002; McGuire et al., 2004; Whittemore et al., 2004; 
McLaughlin et al., 2007; Antoniou et al., 2009). This protective effect seems to increase 
with duration of contraceptive use. The mechanism of this protective effect has not been 
fully elucidated, but it has been suggested that inhibition of ovulation, suppression of 
gonadotropin levels, and increase of progestin levels may all play a role in protecting 
against ovarian cancer (Cibula, 2011). The “incessant ovulation hypothesis” assumes 
ovulation itself to increase ovarian cancer risk because of “damage” to the epithelium 
(Fathalla, 1971; Purdie, 2003; Murdoch, 2005). Another mechanistic hypothesis proposes 
that ovarian mutagenesis is caused by excessive gonadotropin levels that naturally 
fluctuate with a women’s menstrual cycle (Cibula, 2011). On the other hand, 
progesterone, one of the hormones taken in oral contraceptives, has been linked to up-
regulation of the tumor suppressor p53, apoptosis, and lowered cell proliferation, all 
functions aiding in tumor suppression (Bu et al., 1997; Cibula, 2011). 
 In contrast to the situation for ovarian cancer, oral contraceptives may increase 
the risk for breast cancer; Iatrakis (2011) provides evidence for such an effect in BRCA1 
and 2 mutation carriers. Cibula (2011) showed an increase of breast cancer only for 
BRCA1 mutation carriers. This latter effect may be due to increased levels of estrogen 
affecting tumor growth in ER+ breast tumors (Anderson, 2002). However, the literature 
on this point is not consistent; while most studies suggest an increased risk for longer 
duration of oral contraceptive use, others claim no significant increase in risk (Iodice, 
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2010; Narod et al., 2002). It thus appears that more studies are needed that separate 
effects on carriers of the two BRCA genes. 
 Furthermore, many women are interested in how hormone replacement therapy, 
i.e. taking estrogen and/or progestin to relieve menopausal symptoms, will affect their 
cancer risk. This is particularly interesting to BRCA mutation carriers, as many receive 
recommendations from their doctors to undergo prophylactic surgery, i.e. removal of 
target organs as a prevention tool, which can trigger early menopause. Women who have 
their ovaries and uterus removed as a preventive measure due to their BRCA-positive 
status need to know if hormone replacement therapy will increase their cancer risk. A few 
studies on how hormone replacement therapy affects BRCA mutation carriers have been 
conducted and conclude that there is no increase in risk (Kotsopoulos et al., 2006; Biglia, 
2008). However, these studies typically did not separate BRCA1 and BRCA2 mutation 
carriers in their analysis. Again, for conclusive results these two groups must be 
separated due to their differences in tumor characteristics with respect to hormone 
receptors. 
 
  4.3 Sleep Deprivation/Shift Work and Increased Breast and Ovarian Cancer 
 A correlation has been shown between working night shifts and breast cancer risk 
(Schernhammer et al., 2001; Megdal et al., 2005). This increased risk has been suggested 
to be caused by a disruption in natural circadian rhythm (Mahoney, 2010) as well as a 
deficiency of the hormone melatonin, produced at night, that regulates and suppresses 
production of estrogen (Mihu, 2009; compare Fig. 1). Without production of melatonin, 
excess estrogen may be produced, as a known tumor promoter and a vital contributor to 
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onset of breast and ovarian cancer (Anderson, 2002; Mihu, 2009; Merklinger-Gruchala, 
2008). A similar correlation with night shifts has also been shown for ovarian cancer, but 
there was suggestive evidence of a decreased risk for “night people”, or “owls”, 
compared to “morning people”, or “larks” (Bhatti et al., 2013). In a separate study, Lim 
and Saper (2012) recently reported that a single nucleotide polymorphism is correlated 
with whether someone is a “lark” or an “owl”; A-A genotypes woke up about an hour 
earlier than G-G genotypes and A-G genotypes woke up almost exactly in the middle 
(Lim and Saper, 2012). The latter authors also found that this genotype variation is also 
correlated with time of death. I suggest that the results of Bhatti (2013), showing an 
increased risk for ovarian cancer for those who have worked night shifts, but a lower 
increased risk for “night people” might be explained by a protective genetic interaction 
between genes promoting breast and ovarian cancer, such as disruption in the circadian 
rhythm genes and melatonin production, and this nucleotide variation identified by Lim 
and Saper (2012).  
 
 4.4. Interaction of BRCA with Other Genes 
 Henderson and Feigelson (2000) conclude in their review that breast cancer is a 
polygenic disease involving multiple genes in estrogen synthesis and estrogen receptor 
binding. Ovarian cancer is also thought to be polygenic, with an involvement of genes 
affecting FSH (follicle-stimulating hormone) and progesterone levels, both being 
hormones that function in regulation of the menstrual cycle and ovulation (Henderson 
and Feigelson, 2000). Multiple genes are thus responsible for hereditary breast and 
ovarian cancer (Boulton, 2006; Tan, 2008). However, the nature of these interactions is 
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poorly understood (Boulton, 2006). A specific example is the interaction with BRCA and 
insulin-like growth factor 1 (IGF-1, that, as is typical for growth factors, promotes cell 
division; Henningson, 2011). A link between increased IFG-1 and BRCA mutation 
tumors has been proposed (Hudelist, 2007; Pasanisi, 2011; Henningson, 2011). 
Henningson (2011) shows that the normal (un-mutated) BRCA gene suppresses the IGF-
1 promoter, while a faulty BRCA is associated with greater IGF-1 expression. In 
addition, presence of a rare variant of IFG-1, associated with higher IGF-1 levels, in 
BRCA mutation carriers was associated with a younger diagnosis age (Henningson, 
2011).   
Knowledge of gene interactions, such as that between BRCA and IGF-1, can be 
important to BCRA studies; Pasanisi (2011) suggests that BRCA interaction with IFG-1 
modulates penetrance level for BRCA mutation carriers. The proposed interaction 
between the sleep variants and breast and ovarian promoting genes above is another 
example that warrants further attention. For populations with genetic variants that 
increase or decrease the risk for breast and ovarian cancer, whether or not they involve 
BRCA, the causes of these differences in penetrance levels thus needs to be further 
addressed. Conversely, knowledge of prevalence and penetrance differences may aid in 
the discovery of protective or multiplicative genes. Moreover, identification of possible 
additional genetic interactions should further increase treatment options for patients.  
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5. Future Suggested Studies and Areas For Focus in BRCA Research 
  
 5. 1. Molecular Diagnostics 
 Molecular diagnostics in cancer research assesses an individual’s genes, identifies 
specific mutations (among the many possible mutations, see below) harbored by this 
individual, and uses this information as a tool for cancer treatment and, possibly, 
prevention (Kalia, 2013). Currently, this work is only done as part of research projects 
and early phase clinical trials.  
 For a cancer tumor to form, not just one but multiple mutations must be accrued 
(Hanahan and Weinberg, 2000). Each of these mutations must affect components of key 
pathways controlling e.g. cell division, cell death, and DNA repair in the cell cycle to 
overcome the genome’s naturally protective efforts. Because individual tumors possess 
different combinations of genetic mutations, each tumor responds differently to current 
standard cancer treatments (v’ant, 2002; Sim, 2013). Knowledge of these differences is 
needed to prevent and treat cancer. Genotyping, or the sequencing of the specific DNA 
makeup of individual tumors for the exact mutations involved, promises to identify the 
most effective cancer treatments. In turn, such individualized cancer treatments should 
reduce (i) health care cost, (ii) lost time due to ineffective treatments, (iii) unnecessary 
damage to non-cancer cells, and (iv) psychological stress from unproductive therapies. 
 The estrogen receptor status of breast cancer is a good example of the promise of 
molecular diagnostics. Identifying a breast tumor’s presence and numbers of receptors for 
estrogen, progesterone and human epidermal growth factor type 2 can guide in selecting 
appropriate chemotherapies targeting these receptors.  
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 Furthermore, I suggest using molecular diagnostics as a possible preventative 
tool. For individuals with inherited susceptibility mutations, such as BRCA mutations, 
one of the main mutations of the cancer is already known. Once the molecular pathways 
disrupted by the onset of cancer are known, a test for components of this pathway may 
allow early cancer detection.  
 Due to the promise of such research, I suggest that more focus be placed on 
molecular diagnostics in cancer research and in BRCA-specific research in the future. 
 
 5.2. Gene Therapy 
 Gene therapy involves introducing genes into an organism that will get taken up 
into the genome and be expressed (Niazi, 1997). Research on gene therapy to address 
cancer is focused on (i) replacing missing or altered genes with functional, “working” 
genes (e.g. tumor suppressor genes like BRCA 1 and 2, and others like p53; Hanahan and 
Weinberg, 2000; El-Aneed, 2004), (ii) improving a patient's immune response to cancer 
(by stimulating the immune system’s natural ability to attack cancer cells), (iii) insertion 
of genes into cancer cells to make the latter more sensitive to chemotherapy, radiation 
therapy, or other treatments, (iv) introduction of “suicide genes” into a patient's cancer 
cells (a “pro-drug”, as an inactive form of a toxic drug, is given and is activated 
specifically in cancer cells containing “suicide genes”, ”which leads to the destruction of 
those cancer cells” (El-Aneed, 2004), and (v) preventing cancer cells from developing 
new blood vessels (cancer cells exhibit prolific vascularization, or angiogenesis, and stop 
growing if blood supply is cut off; Naumov et al., 2006). 
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 One of the current problems with gene therapy is the difficulty with inserting 
genes into their correct location in the human genome (Fey, 1999; El-Aneed, 2004). 
Genes have to first be introduced into a host via viral vectors, such as retroviruses, 
adenoviruses, adeno-associated viruses or lentiviruses (El-Aneed, 2004), but despite 
successful introductions of genes into these viral vectors and of vectors into the host, 
insertion of the gene in the proper location in the genome has been elusive (El-Aneed, 
2004). Insertion in the wrong location has itself been associated with cancer – 
presumably since insertion into the wrong place in the genome can trigger oncogenes or 
suppress tumor suppressor genes (Baum, 2007). Clearly, more effective techniques are 
needed to deliver genes to specific target cells and locations in the genome. 
 Concerning gene therapy with BRCA genes, much of the available work was 
done by the group of Tait in the late 1990s and early 2000s (Tait, 1998,1999, 2000) in 
search of a vector allowing insertion of a functional (wild type) BRCA1 gene into mouse 
models. In 1998, retroviral-mediated delivery of BRCA1 gene therapy used in mouse 
models (Tait, 1998) was found to be effective in reducing tumor burden and to be 
minimally toxic. Subsequently, twelve human patients with recurrent or persistent 
ovarian cancer and participating in phase-I clinical trial were treated with one to three 
cycles of intraperitoneal (in the abdomen’s peritoneal cavity) vector treatment of BRCA1  
(Tait, 1998). Toxicity was minimal, and the vector was fairly stable and expressed in 
patient tissues (Tait, 1998). Stabilization of the disease, or absence of tumor growth, was 
noticed in eight of the 12 patients, suggesting that the peritoneal cavity may be an 
appropriate site for gene therapy (Tait, 1998). The latter study proved not only that 
BRCA1 was successful in a vector, but also that the peritoneal cavity is a promising 
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candidate for future treatments. Finding an effective site for vector delivery is important 
in the effectiveness of the treatment. However, the effectiveness of this vector diminished 
in phase II trials, such that there was no disease stabilization, and little or no vector 
stability (Tait, 1998). 
 The same group (Tait, 2000) subsequently used MFG-BRCA1, a new retroviral 
BRCA1 vector. Vector stability studies were performed with mice and human serum in 
vitro (in a Petri dish), mice were subsequently injected intraperitoneally with ovarian 
cancer cells, and tumors were allowed to grow for 4 weeks, after which mice were treated 
intraperitoneally with either MFG-BRCA1 or control vectors (Tait, 2000). Survival was 
three-fold greater in these treatments compared to control vectors, and the latter vector 
was more stable than the previously used LXSN-BRCA1sv vector (Tait, 2000).  
 Laura Vannucci and coworkers (2010) used a lentiviral (retrovirus) vector based 
on the feline (cat) immunodeficiency virus (FIV) to import functional, wild type BRCA1 
into human mammary cells with a non-functional BRCA1 gene in vitro. This FIV viral 
vector was used because there are no documented cases of FIV infecting humans, unlike 
HIV (Vannucci, 2010). Lentiviruses are also preferable for gene therapy due to their 
ability to integrate in a directed way into the host genome (causing decreased cancer risk 
from improper insertion), and to ensure long-lasting expression of the transplanted genes 
due to their ability to implant into non-dividing cells (Lever, 2004). Other viruses and 
retroviruses currently used for gene therapy are less effective at these aforementioned 
functions (Lever, 2004). A human epithelial (293T) tumor cell line (obtained from a 24-
year old patient with primary breast cancer and carrying a germ-line mutation in BRCA1) 
was used for the in vitro tests (Vannucci, 2010). Cells showed fully functional BRCA1 
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gene over a period for one month of observation (observation stopped after one month); 
BRCA1-transduced cells repaired DNA double strand breaks more efficiently and grew 
five times faster compared to control cells (Vannucci, 2010). Overall, the latter study 
shows that functional, wild type BRCA1, delivered and expressed into defective cells 
bearing an inactive BRCA1 gene, restores normal gene function and contributes to 
maintaining cell homeostasis in human epithelial cells in vitro. 
 The promise of gene therapy to restore non-functional BRCA cells to functional 
cells is thus considerable. Because of the encouraging developments in this area of 
research, I suggest gene therapy as a continued area for focus research on cancer and 
BRCA mutations. Furthermore, the use of germ line gene therapy to integrate a 
functional gene into the germ line and therefore eradicate mutations from subsequent 
generations, is a particularly promising area for future research. 
 
6. Conclusions  
 In conclusion, more BRCA testing, and more testing of random individuals 
(beyond families with a known elevated cancer risk), needs to be conducted. BRCA 
mutations are found worldwide, but more testing needs to be done in order to accurately 
assess which populations are at higher risk for presence of the faulty gene, and what the 
reasons are for differences in penetrance. Second, BRCA1 and 2 need to be analyzed 
separately, due to their differing characteristics, such as presence or absence of estrogen 
receptors. The latter two genes need to be analyzed separately especially in all studies of 
factors with a possible connection to estrogen levels. Third, studies on the effects of 
lifestyle factors need to include information on exposure to these factors for many years 
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prior to the cancer diagnosis and need to assess synergistic effects of dietary/lifestyle 
factors. Fourth, molecular diagnostics and gene therapy – as showing great promise for 
the treatment and prevention of cancer – should be a key focus of future research. Since 
research progress appears to be hindered by a fracturing of the field into many different 
disciplines, an effort to integrate these multiple disciplines towards more synergistic 
efforts should make research easier, faster and more effective. Additionally, immediate 
suggestions for those with BRCA mutations to lower cancer risk are to follow a diet rich 
and diverse in fruits, vegetables and phytochemicals and low in alcohol, maintain a low 
Body Mass Index, use oral contraceptives for ovarian cancer risk reduction, and get 
enough sleep with a reduction in night activity. 
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